Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WST
WST logo

WST Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
329.110
Open
326.350
VWAP
326.75
Vol
1.48M
Mkt Cap
23.17B
Low
323.200
Amount
483.35M
EV/EBITDA(TTM)
26.27
Total Shares
70.65M
EV
22.86B
EV/OCF(TTM)
31.95
P/S(TTM)
7.39
West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.
Show More

Events Timeline

(ET)
2026-06-01
16:40:00
West Pharmaceutical Appoints Michel Lagarde as CEO
select
2026-05-15 (ET)
2026-05-15
13:30:00
West Pharmaceutical Reports Significant Progress in Cyberattack Recovery
select
link

News

NASDAQ.COM
2.0
06-19NASDAQ.COM
Cardinal Health Continues Growth with Stock Price Surge
  • Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
  • Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
  • Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
  • Rapid Expansion of New Businesses: The company's
NASDAQ.COM
4.5
06-09NASDAQ.COM
US Stocks Close: Nasdaq Hits 5-Week Low Amid Market Rotations
  • Market Volatility: The S&P 500 index fell by 0.26% and the Nasdaq 100 dropped by 1.12% on Tuesday, indicating a shift to a downward trend after an early advance, reflecting investor concerns over tech stocks.
  • Energy Price Impact: WTI crude oil prices plunged by 3% to a seven-week low, leading to widespread declines in energy producers' stocks, which exacerbated the overall market weakness and highlighted the direct impact of oil price fluctuations on related sectors.
  • Real Estate Market Recovery: US existing home sales rose to 4.17 million in April, a five-month high, boosting the stocks of builders and suppliers, indicating that a recovery in the real estate market could provide positive signals for the economy.
  • International Trade Data Improvement: China's May exports increased by 19.4% year-on-year, surpassing expectations, showcasing potential for global economic growth, which may positively influence the US market, despite ongoing uncertainties.
NASDAQ.COM
4.5
06-09NASDAQ.COM
US Stock Market Volatility Amid Falling WTI Crude Prices
  • Mixed Market Performance: The S&P 500 index fell by 0.28%, while the Dow Jones Industrial Average rose by 0.19%, and the Nasdaq 100 index dropped by 0.80%, indicating a divergence in market sentiment, particularly with weakness in chipmakers and software stocks weighing on the broader market.
  • Crude Oil Price Decline: WTI crude oil prices plunged over 3% to a one-week low, primarily due to the ceasefire agreement between Iran and Israel, leading to expectations of further declines in oil prices that could impact the profitability outlook for energy stocks.
  • Positive Economic Data: The US trade deficit narrowed to $55.9 billion in April, better than the expected $56.1 billion, while existing home sales in May rose by 3.2% month-over-month to 4.17 million, indicating resilience in the housing market that may provide support for stocks.
  • Company Movements: United Natural Foods saw its stock drop over 12% after reporting Q3 net sales below expectations, while Nuvalent's stock surged over 38% following GSK's agreement to acquire the company for $10.6 billion, reflecting varied market reactions to company fundamentals.
seekingalpha
6.0
06-09seekingalpha
Barclays Upgrades West Pharmaceutical to Overweight, Predicts Upside
  • Rating Upgrade: Barclays upgraded West Pharmaceutical (WST) from Equal Weight to Overweight, with analysts citing strong fundamentals that could drive near-term upside, reflecting market confidence in the company's future performance.
  • Fundamental Improvement: Analyst Luke Sergott noted that previous overestimations of potential headwinds from multi-dose vials and new oral GLP-1 drugs are not expected to pose significant threats in the coming years, suggesting a more favorable outlook.
  • Leadership Advantage: The leadership of newly appointed CEO Michel Lagarde and CFO Bob McMahon, who joined last year, is highlighted as a key factor that could facilitate the company's growth and diversification over the next few years.
  • Price Target Increase: Barclays raised its price target for WST from $310 to $400, reflecting analysts' optimistic expectations regarding the company's untapped balance sheet capacity and capital deployment flexibility.
NASDAQ.COM
4.5
06-09NASDAQ.COM
US Stocks Rebound as AI Trade Continues to Gain Momentum
  • Market Rebound: The S&P 500 Index rose by 0.93%, the Dow Jones Industrial Average increased by 0.89%, and the Nasdaq 100 Index climbed by 1.17%, indicating a sustained rebound in the artificial intelligence trade that boosts market confidence and investor sentiment.
  • Crude Oil Price Decline: WTI crude oil prices fell by 2% to a one-week low, which lowered inflation expectations and provided support for stocks and bonds, reflecting a positive outlook for future economic growth.
  • Strong China Trade Data: May exports rose by 19.4% year-on-year, exceeding expectations of 15.0%, while imports increased by 27.4%, surpassing the anticipated 26.0%, indicating positive signals for global economic recovery that could further drive market gains.
  • Tech Stocks Lead Gains: Chipmakers and AI infrastructure stocks showed strong performance, with Lam Research up over 4%, and Applied Materials and KLA Corp both rising over 3%, suggesting that the recovery in the tech sector is driving overall market growth.
CNBC
6.0
06-09CNBC
Key Wall Street Rating Changes Overview
  • Toll Brothers Upgrade: KBW upgraded Toll Brothers from market perform to market outperform, reflecting resilient luxury demand and improved fundamentals, which is expected to drive growth in the high-end real estate market.
  • Park Aerospace Initiation: Citizens initiated coverage on Park Aerospace with a market outperform rating and a $42 price target, citing significant growth opportunities in aerospace materials, particularly in key commercial aviation engine programs.
  • Apple Rating Reaffirmed: Morgan Stanley raised its price target on Apple from $330 to $360, noting that WWDC 2026 demonstrated clear progress on Apple's AI roadmap, although monetization will be a long-term endeavor.
  • FuelCell Upgrade to Buy: Canaccord upgraded FuelCell from hold to buy, highlighting that the company has deployed nearly one gigawatt of energy blocks globally over the past two decades, showcasing its technology's viability and market potential.
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
Wall Street analysts forecast WST stock price to rise
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
285.00
Averages
348.70
High
375.00
Current: 0.000
sliders
Low
285.00
Averages
348.70
High
375.00
Barclays
upgrade
AI Analysis
2026-06-09
Reason
Barclays
Price Target
AI Analysis
2026-06-09
upgrade
Reason
Barclays upgraded West…
Wolfe Research
Mike Polark
Peer Perform
to
Outperform
upgrade
$375
2026-06-01
Reason
Wolfe Research
Mike Polark
Price Target
$375
2026-06-01
upgrade
Peer Perform
to
Outperform
Reason
As previously reported, Wolfe Research analyst Mike Polark upgraded West Pharmaceutical to Outperform from Peer Perform with a $375 price target. Q1 was \"juicy good,\" driven by continued GLP1 growth and a return to significant growth in \"everything else\" within the high-value products category, the analyst tells investors. West is levered to injectables which are still growing and widely projected to grow for years to come, the analyst added.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WST
Unlock Now

Valuation Metrics

The current forward P/E ratio for West Pharmaceutical Services Inc (WST.N) is 38.31, compared to its 5-year average forward P/E of 42.00. For a more detailed relative valuation and DCF analysis to assess West Pharmaceutical Services Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
42.00
Current PE
38.31
Overvalued PE
49.18
Undervalued PE
34.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
27.37
Current EV/EBITDA
24.02
Overvalued EV/EBITDA
32.58
Undervalued EV/EBITDA
22.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.74
Current PS
6.46
Overvalued PS
9.48
Undervalued PS
6.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

which stocks to buy short term
Intellectia · 40 candidates
Moving Average Relationship: PriceAboveMA20Week Price Change Pct: $4.00 - $12.00Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
ELV logo
ELV
Elevance Health Inc
74.87B
QCOM logo
QCOM
Qualcomm Inc
158.82B
VTR logo
VTR
Ventas Inc
39.76B
KDP logo
KDP
Keurig Dr Pepper Inc
39.76B
PKG logo
PKG
Packaging Corp of America
18.95B
BKR logo
BKR
Baker Hughes Co
68.37B
daily top stock picks
Intellectia · 121 candidates
Market Cap: >= 2.00BRegion: USRsi Category: moderate, overboughtPrice Change Pct: >= $3.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
URI logo
URI
United Rentals Inc
50.48B
TXN logo
TXN
Texas Instruments Inc
215.15B
HRI logo
HRI
Herc Holdings Inc
3.60B
MOH logo
MOH
Molina Healthcare Inc
7.97B
STM logo
STM
STMicroelectronics NV
39.87B
WST logo
WST
West Pharmaceutical Services Inc
19.78B
what are the best stocks to buy today
Intellectia · 16 candidates
Market Cap: >= 10.00BRegion: USAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.65T
PDD logo
PDD
PDD Holdings Inc
150.14B
QCOM logo
QCOM
Qualcomm Inc
149.82B
SMFG logo
SMFG
Sumitomo Mitsui Financial Group, Inc
148.10B
SNY logo
SNY
Sanofi SA
114.04B
CEG logo
CEG
Constellation Energy Corp
106.46B
what is the best stock to invest 6/fev
Intellectia · 31 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
BR logo
BR
Broadridge Financial Solutions Inc
22.70B
AMZN logo
AMZN
Amazon.com Inc
2.39T
NFLX logo
NFLX
Netflix Inc
340.62B
CRM logo
CRM
Salesforce Inc
177.98B
CCI logo
CCI
Crown Castle Inc
37.61B
DELL logo
DELL
Dell Technologies Inc
76.13B
show me stocks strong buy
Intellectia · 16 candidates
Analyst Consensus: Strong BuyEps 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.64T
MSFT logo
MSFT
Microsoft Corp
3.20T
AVGO logo
AVGO
Broadcom Inc
1.57T
ABT logo
ABT
Abbott Laboratories
190.06B
INTU logo
INTU
Intuit Inc
138.84B
BSX logo
BSX
Boston Scientific Corp
138.71B
tell me which stocks are now strong buy
Intellectia · 22 candidates
Market Cap Category: large, megaAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.56T
MSFT logo
MSFT
Microsoft Corp
3.46T
AVGO logo
AVGO
Broadcom Inc
1.52T
MA logo
MA
Mastercard Inc
471.21B
ABT logo
ABT
Abbott Laboratories
186.79B
UBER logo
UBER
Uber Technologies Inc
171.03B
best stocks to invest in 2026 q1
Intellectia · 21 candidates
Market Cap: >= 5.00BMarket Cap Category: large, midAnalyst Consensus: Strong Buy, Moderate BuyReturn On Equity: >= 12.0%Target Price Upside Potential: MoreAbovePriceOne Month Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
MORN logo
MORN
Morningstar Inc
8.63B
KSPI logo
KSPI
Kaspi.kz AO
14.51B
MANH logo
MANH
Manhattan Associates Inc
10.01B
LOGI logo
LOGI
Logitech International SA
13.49B
TTD logo
TTD
Trade Desk Inc
17.09B
PDD logo
PDD
PDD Holdings Inc
150.37B

Whales Holding WST

M
Moore Capital Management, LP
Holding
WST
+16.00%
3M Return
J
Jacobs Levy Equity Management Inc
Holding
WST
+15.94%
3M Return
A
Annex Advisory Services, LLC
Holding
WST
+14.60%
3M Return
A
Artisan Partners Limited Partnership
Holding
WST
+12.91%
3M Return
S
Stichting Pensioenfonds ABP
Holding
WST
+11.93%
3M Return
N
Nan Shan Life Insurance Co., Ltd.
Holding
WST
+11.45%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is West Pharmaceutical Services Inc (WST) stock price today?

The current price of WST is 327.95 USD — it has increased 1.35

What is West Pharmaceutical Services Inc (WST)'s business?

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.

What is the price predicton of WST Stock?

Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is West Pharmaceutical Services Inc (WST)'s revenue for the last quarter?

West Pharmaceutical Services Inc revenue for the last quarter amounts to 844.90M USD, increased 21.05

What is West Pharmaceutical Services Inc (WST)'s earnings per share (EPS) for the last quarter?

West Pharmaceutical Services Inc. EPS for the last quarter amounts to 1.92 USD, increased 56.10

How many employees does West Pharmaceutical Services Inc (WST). have?

West Pharmaceutical Services Inc (WST) has 10800 emplpoyees as of June 20 2026.

What is West Pharmaceutical Services Inc (WST) market cap?

Today WST has the market capitalization of 23.17B USD.